Anxiety level of early- and late-stage prostate cancer patients.
ABSTRACT Anxiety can worsen prostate cancer patients' decision making and quality of life. Early identification of anxiety disorders is thus very important for excellent prostate cancer treatment. This study aimed to determine the levels of anxiety in patients with early-stage prostate cancer compared with advanced-stage disease.
This cross-sectional study was performed at the Department of Urology, 'Cipto Mangunkusumo' Hospital, Faculty of Medicine, University of Indonesia. The subjects were early-stage prostate cancer patients and advanced-stage prostate cancer patients with bone metastatic lesions proved by bone scan. Comparative analysis was done to analyze anxiety scores assessed by use of an 11-item modified Memorial Anxiety Scale for Prostate Cancer (MAX-PC) questionnaire. We also assessed the relationship of the MAX-PC score with age, prostate-specific antigen (PSA) value, number of bone metastases, and pain. Data were analyzed by using SPSS ver. 17 (SPSS Inc.).
There were 34 subjects with early-stage prostate cancer and 34 subjects with advanced-stage prostate cancer. We found that the mean anxiety score was significantly lower (P=0.0001) in the early-stage prostate cancer group (8.32±3.65) than in the advanced-stage prostate cancer group (12.61±4.56). Nine subjects had a pathological MAX-PC score (≥16), of whom 1 subject had early-stage disease and 8 subjects had advanced-stage disease. Furthermore, there were significant positive correlations (P<0.001) between MAX-PC score and visual analogue scale pain score (r=0.633), PSA value (r=0.263), and number of bone metastatic lesions (r=0.464). However, the correlation between age and anxiety score was not significant (P=0.170).
The MAX-PC anxiety score was significantly associated with the stage of prostate cancer. Furthermore, visual analogue scale pain score, PSA value, and number of bone metastatic lesions can also affect the MAX-PC anxiety score.
- SourceAvailable from: David V. Sheehan[Show abstract] [Hide abstract]
ABSTRACT: The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short structured diagnostic interview, developed jointly by psychiatrists and clinicians in the United States and Europe, for DSM-IV and ICD-10 psychiatric disorders. With an administration time of approximately 15 minutes, it was designed to meet the need for a short but accurate structured psychiatric interview for multicenter clinical trials and epidemiology studies and to be used as a first step in outcome tracking in nonresearch clinical settings. The authors describe the development of the M.I.N.I. and its family of interviews: the M.I.N.I.-Screen, the M.I.N.I.-Plus, and the M.I.N.I.-Kid. They report on validation of the M.I.N.I. in relation to the Structured Clinical Interview for DSM-III-R, Patient Version, the Composite International Diagnostic Interview, and expert professional opinion, and they comment on potential applications for this interview.The Journal of Clinical Psychiatry 02/1998; 59 Suppl 20:22-33;quiz 34-57. · 5.14 Impact Factor
- BMJ Clinical Research 12/2001; 323(7320):1055-8. · 14.09 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The results of a 1997 meta-analysis of the rates of erectile function after external beam radiotherapy (EBRT) and radical prostatectomy have been widely used in patient and professional education materials and as a reference against which new findings are compared. With a number of recent publications, it is now possible to update this analysis and compare brachytherapy with or without EBRT with EBRT alone, standard and nerve-sparing radical prostatectomy, and cryotherapy. A comprehensive literature review and subsequent meta-analysis of the rates of erectile dysfunction associated with the treatments of localized prostate carcinoma was conducted. A simple logistic regression analysis was used to combine the data from the 54 articles that met the selection criteria. The predicted probability of maintaining erectile function after brachytherapy was 0.76, after brachytherapy plus EBRT 0.60, after EBRT 0.55, after nerve-sparing radical prostatectomy 0.34, after standard radical prostatectomy 0.25, and after cryotherapy 0.13. When only studies reporting > or = 2 years follow-up were considered, the only significant change was a decline in the probability for nerve-sparing radical prostatectomy. No brachytherapy studies had a follow-up of > or = 2 years. When the probabilities were adjusted for age, the spread between the RT methods and surgical approaches was greater. The differences in the probability of maintaining erectile function after different treatments of localized prostate cancer are significant.International Journal of Radiation OncologyBiologyPhysics 12/2002; 54(4):1063-8. · 4.18 Impact Factor
Copyright © 2013 Asian Pacific Prostate Society (APPS)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN: 2287-8882 • eISSN: 2287-903X
P R O S T A T E
Anxiety level of early- and late-stage prostate cancer
Charles Johanes, Richard Arie Monoarfa, Raden Irawati Ismail1, Rainy Umbas
Departments of Urology and 1Psychiatry, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia, Jakarta, Indonesia
Purpose: Anxiety can worsen prostate cancer patients’ decision making and quality of life. Early identification of anxiety disorders is
thus very important for excellent prostate cancer treatment. This study aimed to determine the levels of anxiety in patients with early-
stage prostate cancer compared with advanced-stage disease.
Methods: This cross-sectional study was performed at the Department of Urology, ‘Cipto Mangunkusumo’ Hospital, Faculty of Medicine,
University of Indonesia. The subjects were early-stage prostate cancer patients and advanced-stage prostate cancer patients with
bone metastatic lesions proved by bone scan. Comparative analysis was done to analyze anxiety scores assessed by use of an 11-item
modified Memorial Anxiety Scale for Prostate Cancer (MAX-PC) questionnaire. We also assessed the relationship of the MAX-PC score
with age, prostate-specific antigen (PSA) value, number of bone metastases, and pain. Data were analyzed by using SPSS ver. 17 (SPSS
Results: There were 34 subjects with early-stage prostate cancer and 34 subjects with advanced-stage prostate cancer. We found that
the mean anxiety score was significantly lower (P=0.0001) in the early-stage prostate cancer group (8.32±3.65) than in the advanced-
stage prostate cancer group (12.61±4.56). Nine subjects had a pathological MAX-PC score (≥16), of whom 1 subject had early-stage
disease and 8 subjects had advanced-stage disease. Furthermore, there were significant positive correlations (P<0.001) between
MAX-PC score and visual analogue scale pain score (r=0.633), PSA value (r=0.263), and number of bone metastatic lesions (r=0.464).
However, the correlation between age and anxiety score was not significant (P=0.170).
Conclusions: The MAX-PC anxiety score was significantly associated with the stage of prostate cancer. Furthermore, visual analogue
scale pain score, PSA value, and number of bone metastatic lesions can also affect the MAX-PC anxiety score.
Keywords: Prostatic neoplasms, Neoplasm staging, Anxiety disorders, Pain measurement
Prostate Int 2013;1(4):177-182 • http://dx.doi.org/10.12954/PI.13027
Corresponding author: Rainy Umbas
Division of Urology Department of Surgery, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia, Jl. Diponegoro No.71, Jakarta 10430, Indonesia
E-mail: firstname.lastname@example.org / Tel: +62213923631 / Fax: +62213145592
Submitted: 26 September 2013 / Accepted after revision: 21 November 2013
Prostate cancer is the most common carcinoma among men
in Western countries, and the incidence rate is increasing in
Asian countries . Men diagnosed with prostate cancer have
a higher anxiety level and a higher risk of developing depres-
sion than do healthy men . They also have a tendency for
suicide that is 4 times higher than the risk in healthy indi-
viduals . Prostate cancer patients also experience serious
challenges to their self-esteem [4,5], especially concerning
their masculinity [6,7]. Some of the unpleasant experiences
that prostate cancer patients may have are the fear of bearing
their unpredictable future ; pain; fatigue; nausea (due to
medication); loss of social and physical capabilities, especially
sexual capability, as the result of hormonal therapy ; and
erectile dysfunction, which occurs in 30% to 70% of patients
who undergo prostate surgery [10,11]. The patient’s response
to those unpleasant experiences may be a trigger of anxiety
and depression in this population . Anxiety and depres-
sion also affect the quality of life of patients with prostate
Johanes, et al. Anxiety level of early and late stage prostate cancer patients
cancer, especially those receiving hormonal therapy . Fur-
thermore, anxiety and depression can worsen the patient’s
decision making. For these reasons, early identification of
affective disorders is very important for making good prostate
cancer treatment decisions [4,14]. Unfortunately, only a few
studies about quality of life and the psychological character-
istics of prostate cancer patients have been conducted in Asia
. In general, those studies showed that the anxiety level
of patients with cancer was proportional to the stage of the
disease . The aim of the present study was to determine
the anxiety level of patients with early-stage prostate cancer
compared with that of patients with advanced-stage disease
at our institution.
MATERIALS AND METHODS
The subjects of this study were newly diagnosed patients with
early-stage or advanced-stage prostate cancer registered in
the Department of Urology, “Cipto Mangunkusumo” Hospi-
tal. Advanced-stage prostate cancer was defined as metastatic
prostate cancer proved by bone scan. Exclusion criteria were
subjects who could not communicate or fill out the anxiety or
visual analogue scale (VAS) form.
2. Data collection
Subjects who met the inclusion criteria were requested to
participate in this study. We collected data on age, anxiety scale
score, pain VAS score, number of bone metastatic lesions, and
prostate-specific antigen (PSA) value. Anxiety was assessed by
use of the modified memorial anxiety scale for prostate can-
cer (MAX-PC) and pain was assessed by use of a VAS (score,
1 to 10). The modified MAX-PC questionnaire consisted of 11
questions, which are shown in the Appendix. The MAX-PC
questionnaire was validated in a study assessing anxiety by
Roth et al.  in New York and in a study by Van den Bergh
et al.  in Rotterdam. The number of study subjects was 34
with early-stage prostate cancer and 34 with advanced-stage
prostate cancer. Subjects who had a MAX-PC score ≥ 16 were
classified in the pathological group [17-19]. Approval for this
study was obtained from the health research ethics commit-
tee in the Faculty of Medicine, “Cipto Mangunkusumo” Hos-
pital, University of Indonesia.
3. Data analysis
Data were analyzed and presented in a frequency distribu-
tion table. Comparison of anxiety scores between early-stage
prostate cancer patients and advanced-stage prostate cancer
patients was performed by use of independent t-tests. If the
independent t-test requirement was not met, the Mann-Whit-
ney test was used. The study confounding factors were VAS,
PSA value, number of bone metastatic lesions, and age. The
relationship between age, VAS, and PSA value with the anxi-
ety score was analyzed by using the Pearson correlation test.
If the Pearson correlation test requirement was not met, the
Spearman test was used. The data were analyzed by using the
Statistical Package for the SPSS ver. 17 (SPSS Inc., Chicago, IL,
USA). The analysis was considered significant if the P-value
Of the 68 subjects, there were 34 early-stage and 34 advanced-
stage prostate cancer patients. The mean age of the subjects
was 67.99±8.724 years. The mean MAX-PC score was 10.47±
4.64. Of the 68 subjects, 59 subjects did not have a pathologi-
cal MAX-PC score (MAX-PC score<16). Nine subjects, how-
ever, had pathological MAX-PC scores. Of those 9 subjects,
1 subject was an early-stage prostate cancer patient and 8
subjects were advanced-stage prostate cancer patients. The
mean VAS score was 4.05±1.99. Other characteristics of the
data set can be seen in Table 1.
As stated above, the mean MAX-PC score in this study
was 10.47±4.64, with a median value of 9 (range, 1–23), and
the mean VAS score was 4.05±1.99, with a median value of
4 (range, 1–8). We found a significant difference in the anxi-
ety score and the mean VAS score between the groups with
early-stage and advanced-stage prostate cancer. The mean
anxiety score in the group of early-stage prostate cancer
patients (8.32±3.65) was significantly lower than the mean
anxiety score in the advanced-stage prostate cancer group
(12.61±4.56). Analysis of this relationship is shown in Tables
2 and 3.
The relationship between confounding factors (age, VAS,
PSA value, number of bone metastatic lesions) and the MAX-
Table 1. Subject characteristics in the early- and advanced-
stage prostate cancer groups
No. of bone
NA NA 12.856.50
NA, not applicable.
Vol. 1 / No. 4 / December 2013
PC score was analyzed by using the Spearman test. This study
found that the correlation between age and MAX-PC was not
significant with no strong positive correlation. Interestingly,
a significant association was found between VAS scores and
the MAX-PC score (P<0.001) with a very strong positive cor-
relation (r=0.633), which could mean that the greater the VAS
score the greater the MAX-PC score. These correlations are
shown in Table 4.
Problems in treating cancer patients include not only the can-
cer itself, but also the quality of life and psychological problems
of patients. Anxiety and depression are the most common
psychological disorders in patients with cancer . It has
been reported that the level of anxiety and depression is high-
er in prostate cancer patients than in healthy men. The MAX-
PC is a valid and reliable method for identifying anxiety re-
lated to prostate cancer [19,20]. In this study, the mean MAX-
PC score was 10.47±4.64. Similar results were reported by
Van den Bergh et al. , who found a mean MAX-PC score
of 9.3±6.8. The analysis of the relationship between prostate
cancer stage and anxiety scores showed a significant differ-
ence in the mean MAX-PC score (P=0.0001) between the ear-
ly-stage prostate cancer group (8.32±3.65) and the advanced-
stage prostate cancer group (12.61±4.56). Vodermaier et al.
 reported the same findings that anxiety symptoms were
more commonly found in metastatic prostate cancer patients
than in nonmetastatic prostate cancer patients.
Another study by Bill-Axelson et al.  suggested that the
hospitalization rate related to psychiatric symptoms (anxiety)
will increase along with the diagnosis of prostate cancer. In
patients with advanced-stage cancer, there would be more
treatment for anxiety with a relative risk of 2.28 (95% confi-
dence interval, 1.45–3.57) compared with early-stage cancer
. The most common metastatic site of prostate cancer is
bone. In prostate cancer, bone metastatic lesions result in lo-
calized pain . In our study, the pain score (VAS) in patients
with advanced-stage prostate cancer was significantly higher
than that in patients with early-stage prostate cancer. In this
study, there were some confounding variables significantly
related to the MAX-PC score (P<0.05). These were the level of
pain (VAS score), PSA value, and number of bone metastatic
lesions. The VAS score was significantly correlated with the
anxiety level (MAX-PC score). Cancer pain in prostate cancer
patients was considered to have a major effect on anxiety level
(r=0.633, P<0.001); therefore, the proper management of
pain is important.
The high level of anxiety could affect patient decision mak-
ing in determining the treatment of choice [19,23]. A study
by Latini et al.  showed that early-stage prostate cancer
patients who have a high level of anxiety tend to make an
early decision for more aggressive therapy compared with
undergoing active surveillance. The existence of this anxiety
disorder along with depression would interfere in daily activi-
ties, reduce the quality of life, and increase the incidence of
suicide of prostate cancer patients [3,7,9]. Factors that could
increase the risk of anxiety in cancer patients are advanced
stage of cancer, previous history of anxiety, lack of family sup-
port, activity limitations due to cancer, other comorbidities,
and unresolved cancer pain . In the National Compre-
hensive Cancer Network distress guideline version 2.2013,
an indication for referring a cancer patient to mental health
services or social work and counseling services is a Distress
Thermometer value of 4 or more with social, family, physical,
emotional, and other medical problems. In assessing prostate
cancer–related anxiety, we have not yet found a cutoff score
Table 2. Analysis of the relationship between prostate cancer
stage and MAX-PC score
Prostate cancer stageMAX-PC value
Values are presented as mean±standard deviation (range).
MAX-PC, memorial anxiety scale for prostate cancer.
Table 3. Comparison of mean VAS pain scores in the early- and
advanced-stage prostate cancer groups
Prostate cancer stageValue
Values are presented as mean±standard deviation (range).
VAS, visual analogue scale.
Table 4. Correlation of MAX-PC scores with age, VAS, PSA value,
and number of bone metastatic lesions
Correlation coefficient with
No. of bone
MAX-PC, memorial anxiety scale for prostate cancer; VAS, visual ana-
logue scale; PSA, prostate-specific antigen.
Johanes, et al. Anxiety level of early and late stage prostate cancer patients
on the MAX-PC for referral to mental health services (psy-
chiatry). Despite some research on the psychological needs
of men with prostate cancer in Asian countries, it is difficult
to draw clear conclusions about the impacts of prostate can-
cer on the psychological health of Asian men with prostate
cancer . Further investigations are required to determine
the cutoff score on the MAX-PC questionnaire for referral to
mental health services.
The limitations of this study were the relatively small num-
ber of study subjects (34 patients in each group) and the lack
of guidelines in terms of psychiatric treatment for patients
with high levels of anxiety. This study also did not examine
the effect of the high level of anxiety on patient quality of life
and their therapy selection. Future studies should be con-
ducted to determine the cutoff value of MAX-PC score for re-
ferral by use of the MAX-PC instrument in combination with
a psychiatric diagnostic instrument, such as the Mini-Inter-
national Neuropsychiatric Interview for The Diagnostic and
Statistical Manual of Mental Disorders (MINI, DSM-IV). The
MINI is a short, structured diagnostic interview developed in
1990 by psychiatrists and clinicians in the United States and
Europe for DSM-IV and International Statistical Classification
of Diseases-10th revision psychiatric disorders .
In conclusion, advanced-stage prostate cancer was sig-
nificantly related to a high level of anxiety (MAX-PC score).
Furthermore, VAS scores, PSA value, and the number of bone
metastatic lesions might affect the anxiety (MAX-PC score)
of patients with prostate cancer. Study of larger populations
should be done to acquire a cutoff value of the MAX-PC score
for better management of mental health issues in prostate
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
1. The GLOBOCAN project [Internet]. Lyon: International Agen-
cy for Research on Cancer; c2010 [cited 2013 Jan 1]. Available
2. Kronenwetter C, Weidner G, Pettengill E, Marlin R, Crutch-
field L, McCormac P, et al. A qualitative analysis of interviews
of men with early stage prostate cancer: the Prostate Cancer
Lifestyle Trial. Cancer Nurs 2005;28:99-107.
3. Llorente MD, Burke M, Gregory GR, Bosworth HB, Grambow
SC, Horner RD, et al. Prostate cancer: a significant risk factor
for late-life suicide. Am J Geriatr Psychiatry 2005;13:195-201.
4. Bennett G, Badger TA. Depression in men with prostate can-
cer. Oncol Nurs Forum 2005;32:545-56.
5. Couper JW, Bloch S, Love A, Duchesne G, Macvean M, Kis-
sane DW. The psychosocial impact of prostate cancer on
patients and their partners. Med J Aust 2006;185:428-32.
6. Kiss A, Meryn S. Effect of sex and gender on psychosocial as-
pects of prostate and breast cancer. BMJ 2001;323:1055-8.
7. Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Hud-
dart R, et al. Prostate cancer patients’ support and psycholog-
ical care needs: Survey from a non-surgical oncology clinic.
8. Nelson CJ. An argument to screen for distress in men diag-
nosed with early-stage prostate cancer. Nat Clin Pract Urol
9. Roberts KJ, Lepore SJ, Helgeson V. Social-cognitive correlates
of adjustment to prostate cancer. Psychooncology 2006;15:183-
10. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erec-
tile function after treatment of localized prostate carcinoma.
Int J Radiat Oncol Biol Phys 2002;54:1063-8.
11. Vale J. Erectile dysfunction following radical therapy for pros-
tate cancer. Radiother Oncol 2000;57:301-5.
12. Sharpley CF, Bitsika V, Christie DR. Understanding the causes
of depression among prostate cancer patients: development
of the Effects of Prostate Cancer on Lifestyle Questionnaire.
13. Wibowo JR, Umbas R. Quality of life in prostate cancer pa-
tients treated with hormonal therapy. Medika 2004;30:707-15.
14. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P.
Prospective study of men’s psychological and decision-relat-
ed adjustment after treatment for localized prostate cancer.
15. Chambers SK, Hyde MK, Ip DF, Dunn JC, Gardiner RA. Sys-
tematic review of research into the psychological aspects of
prostate cancer in Asia: what do we know? Asian Pac J Can-
cer Prev 2013;14:2621-6.
16. Vodermaier A, Linden W, MacKenzie R, Greig D, Marshall C.
Disease stage predicts post-diagnosis anxiety and depression
only in some types of cancer. Br J Cancer 2011;105:1814-7.
17. Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI,
Curley-Smart T, et al. The memorial anxiety scale for prostate
cancer: validation of a new scale to measure anxiety in men
with with prostate cancer. Cancer 2003;97:2910-8.
18. van den Bergh RC, Korfage IJ, Borsboom GJ, Steyerberg EW,
Essink-Bot ML. Prostate cancer-specific anxiety in Dutch pa-
tients on active surveillance: validation of the memorial anxi-
ety scale for prostate cancer. Qual Life Res 2009;18:1061-6.
Vol. 1 / No. 4 / December 2013
19. Dale W, Hemmerich J, Bylow K, Mohile S, Mullaney M,
Stadler WM. Patient anxiety about prostate cancer inde-
pendently predicts early initiation of androgen deprivation
therapy for biochemical cancer recurrence in older men: a
prospective cohort study. J Clin Oncol 2009;27:1557-63.
20. van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T,
Schroder FH, Bangma CH, et al. Anxiety and distress during
active surveillance for early prostate cancer. Cancer 2009;115:
21. Bill-Axelson A, Garmo H, Nyberg U, Lambe M, Bratt O, Stat-
tin P, et al. Psychiatric treatment in men with prostate cancer:
results from a Nation-wide, population-based cohort study
from PCBaSe Sweden. Eur J Cancer 2011;47:2195-201.
22. Catalona WJ, Han M. Definitive therapy for localized prostate
cancer: an overview. In: Wein AJ, Kavoussi LR, Novick AC,
Partin AW, Peters CA, editors. Campbell-Walsh urology. 10th
ed. Philadelphia: Saunders; 2012:2771-88.
23. Fact sheet: understanding and managing anxiety when liv-
ing with cancer [Internet]. Victorial: Peter MacCallum Cancer
Centre; c2012 [cited 2013 Jan 21]. Available from: http://peter-
24. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane
J, et al. The relationship between anxiety and time to treat-
ment for patients with prostate cancer on surveillance. J Urol
2007;178(3 Pt 1):826-31.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J,
Weiller E, et al. The Mini-International Neuropsychiatric In-
terview (M.I.N.I.): the development and validation of a struc-
tured diagnostic psychiatric interview for DSM-IV and ICD-
10. J Clin Psychiatry 1998;59 Suppl 20:22-33.